Podcast: Play in new window | Download
Summary
In episode 706 of the 40+ Fitness Podcast, Coach Allan speaks with David Knapp, a leading voice in the GLP-1 medication community known for his patient-centric approach to sharing information about weight loss, obesity, and type 2 diabetes. Through his platform On the Pen, Knapp has built a community of over 100,000 individuals navigating their journey with GLP-1 medications, and his work has been featured in Fortune, Bloomberg, Yahoo Finance, and Business Insider. He is the author of the book Decoding GLP-1: A Guide for Friends and Family of Those on the Pen.
Knapp shares his personal story of struggling with obesity from his late teens, cycling through the Atkins and ketogenic diets for roughly 17 years, and ultimately being diagnosed with type 2 diabetes at age 37 while weighing 319 pounds. He explains that after a year of strict keto he lost only 7 pounds and his insulin levels remained high, which led him to the class of GLP-1 medications.
The conversation covers the science behind incretin hormones and GLP-1, the history of these drugs from a peptide isolated from Gila monster venom, the current and future medications, the concept of food noise, the spectrum of compounded and research-grade products, and the stigma surrounding obesity and these medications. Both stress the importance of medical supervision, adequate protein, and resistance training to preserve muscle during weight loss.
Links
- On the Pen (David Knapp’s website, podcast, and community)
- 40+ Fitness Facebook Group
- Get Decoding GLP-1 on Amazon
Key Takeaways
- Obesity is described as a chronic relapsing disease driven by biology and hormones, not simply a calorie-in, calorie-out or willpower problem.
- Incretin hormones are released by the body in response to nutrient intake; GLP-1, the most prominent, stimulates the beta cells in the pancreas to release insulin and signals satiety in the brain. In diabetic and obese people, an enzyme called DPP4 destroys these hormones in higher abundance.
- Excess insulin floating in the bloodstream creates a hormonal environment that makes weight loss very difficult, since insulin’s number one job is to store energy; a person can have a corrected A1C while insulin levels remain off the charts.
- GLP-1 drugs originated from a peptide called Exendin-4 isolated from Gila monster venom; the first medication, Byetta (exenatide), was FDA-approved in the early 2000s, so these drugs have existed for over 20 years.
- Newer drugs like tirzepatide (Mounjaro, Zepbound) act on GIP and, in MRI brain-scan studies, meaningfully dim the brain areas that respond to highly palatable food, quieting the constant nagging hunger known as food noise.
- The medication landscape is evolving quickly, with future drugs such as CagriSema, a triple agonist retatrutide (which revs metabolism to burn fat), and combinations with myostatin inhibitors to preserve or build muscle.
- Compounded and research-grade products exist on a spectrum of safety; Knapp warns strongly against research-grade, for-research-only peptides with no doctor supervision, and notes that oral drops or unprotected oral peptides are largely ineffective because the peptide is broken down or not properly wrapped.
- Because any rapid weight loss risks losing lean muscle (and even heart tissue), prioritizing adequate protein and resistance training under good medical and dietary supervision is essential when on these medications.
Another Episode You May Enjoy
Episode 729 – A playbook for stopping GLP-1 medications with Dr. Jim Hill
Episode Notes
Podcast: 40+ Fitness
Episode: 706
Published: 2025-08-05
Host: Allan Misner (aka Coach Allan), author of The Wellness Roadmap
Guest(s): David Knapp, a leading voice in the GLP1 medication community, known for his patient centric approach to sharing information about weight loss, obesity and type 2 diabetes, Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Listen & Subscribe: Apple Podcasts · Spotify · YouTube (audio only)